CN117327708A - Ppfia1在肝细胞癌治疗、诊断以及预后评估中的应用 - Google Patents
Ppfia1在肝细胞癌治疗、诊断以及预后评估中的应用 Download PDFInfo
- Publication number
- CN117327708A CN117327708A CN202311510675.6A CN202311510675A CN117327708A CN 117327708 A CN117327708 A CN 117327708A CN 202311510675 A CN202311510675 A CN 202311510675A CN 117327708 A CN117327708 A CN 117327708A
- Authority
- CN
- China
- Prior art keywords
- ppfia1
- hepatocellular carcinoma
- expression
- gene
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101001020310 Homo sapiens Liprin-alpha-1 Proteins 0.000 title claims abstract description 58
- 102100035684 Liprin-alpha-1 Human genes 0.000 title claims abstract description 58
- 206010073071 hepatocellular carcinoma Diseases 0.000 title claims abstract description 57
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title claims abstract description 50
- 238000004393 prognosis Methods 0.000 title claims abstract description 21
- 238000003745 diagnosis Methods 0.000 title claims abstract description 17
- 238000011156 evaluation Methods 0.000 title claims abstract description 11
- 238000011282 treatment Methods 0.000 title abstract description 12
- 230000014509 gene expression Effects 0.000 claims abstract description 41
- 101150039932 PPFIA1 gene Proteins 0.000 claims abstract description 27
- 239000002773 nucleotide Substances 0.000 claims abstract description 4
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 4
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 3
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 10
- 239000004055 small Interfering RNA Substances 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 239000003147 molecular marker Substances 0.000 claims description 8
- 230000002452 interceptive effect Effects 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 5
- 238000002626 targeted therapy Methods 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 3
- 238000011144 upstream manufacturing Methods 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 abstract description 7
- 206010027476 Metastases Diseases 0.000 abstract description 6
- 230000009401 metastasis Effects 0.000 abstract description 6
- 238000010837 poor prognosis Methods 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 230000002596 correlated effect Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 52
- 108090000623 proteins and genes Proteins 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 14
- 238000010586 diagram Methods 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 241000699660 Mus musculus Species 0.000 description 12
- 238000011580 nude mouse model Methods 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 8
- 108010087230 Sincalide Proteins 0.000 description 7
- 238000010609 cell counting kit-8 assay Methods 0.000 description 7
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 7
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000003197 gene knockdown Methods 0.000 description 6
- 208000014018 liver neoplasm Diseases 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000029918 bioluminescence Effects 0.000 description 3
- 238000005415 bioluminescence Methods 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000009456 molecular mechanism Effects 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000011794 NU/NU nude mouse Methods 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- -1 dNTP Chemical compound 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 1
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明提供了PPFIA1在肝细胞癌治疗、诊断以及预后评估中的应用,PPFIA1基因的核苷酸序列如SEQ ID NO.1所示。本发明研究结果表明:与正常对照组织相比,肝细胞癌患者组织中PPFIA1的表达水平存在上调,且与患者的不良预后显著相关;进一步实验结果表明:抑制PPFIA1的表达可以抑制肝细胞癌细胞增殖及转移,故抑制PPFIA1的表达可作为治疗肝细胞癌的一种新的治疗靶点,且具有良好的临床应用价值。
Description
技术领域
本发明属于分子生物学技术领域,特别涉及PPFIA1在肝细胞癌治疗、诊断以及预后评估中的应用。
背景技术
肝细胞癌(hepatellular carcinoma,HCC)是一种常见的消化系统恶性肿瘤,全球范围内其发病率和死亡率分别居第六位和第四位。虽然在临床和实验癌症治疗方面取得了很大的进展,但由于术后肿瘤复发转移率高,HCC患者的整体预后较差。既往研究表明,HCC的发展可能是一个多因素病因和多基因交替的多步骤过程,但HCC转移的具体分子机制尚不清楚。因此,更好地了解HCC转移的潜在分子机制对肝癌的预后和靶向治疗具有重要意义。而肝癌则又被认为是异质性最高的肿瘤,深入了解其异质性的分子机制是发现潜在临床治疗策略的必要条件,且考虑到不同个体的差异影响,患者之间的预后存在很大差异。为了能够及时且准确的依据不同患者情况做出诊断并制定个体化治疗方案,寻找简单有效且精准的生物标志物用于肝细胞癌患者的预后诊断对于临床治疗有着十分重要的临床意义。
发明内容
本发明的目的在于解决现有技术中所存在的肝细胞癌术后肿瘤复发转移率高,整体预后较差的技术问题,提供一种与肝细胞癌发生、发展高度相关的基因,即PPFIA1基因。通过以PPFIA1作为标记物,用于肝细胞癌治疗、诊断以及预后评估,能够及时且准确的依据不同患者情况做出诊断,并制定个体化的治疗方案,对肝细胞癌的临床治疗具有十分重要的临床意义。
本发明的目的可以通过以下技术方案实现:
本发明的第一方面提供了一种与肝细胞癌相关的分子标记物PPFIA1,PPFIA1基因的核苷酸序列如SEQ ID NO.1所示。
SEQ ID NO.1:
atgatgtgcgaggtgatgccgaccatcagcgaagcagaaggcccccctggaggaggtggaggccatggttccggctccccttcacagccagatgcagattcacattttgaacagttgatggtctccatgctagaagaaagggaccgccttcttgatacactgagagagactcaagaaacgctggccttaacccaggggaagttacacgaggttggtcatgaaagagattccttgcagagacagctcaacacggcacttccacaggagttcgcagcacttactaaagaactcaatgtatgcagggaacagctccttgaaaggg
aagaagaaattgctgaactgaaagcagaaaggaataacaccaggctgctgttagagcatttggaatgccttgtctccaggc
atgagcggtctcttaggatgaccgtggtgaagagacaagcgcagtctccagcaggcgtgtccagcgaagtggaagtgct
gaaagcactgaagtccttatttgaacaccacaaagctctggatgaaaaggtgagagagcgattacgagtagcacttgaaag
atgtagtttgttagaagaggaattaggtgccacacacaaagagctaatgattcttaaagaacagaataatcagaaaaaaactc
taacagatggagtgctggacataaaccatgaacaagaaaatacaccaagcacgagtggaaagagatcttctgatggttcttt
aagccacgaggaagaccttgctaaagtaattgagctccaagaaatcataagtaagcagtcaagggaacagagccaaatga
aagaacgcctggcttccctttccagtcatgtgacagaactggaagaggatctggacacggctagaaaagatctcatcaaat
ctgaagaaatgaacacaaaattgcaacgagatgtccgtgaagccatggcccaaaaggaagatatggaagagagaatcac
tactcttgaaaaacgctacctcgctgcacagcgtgaagccacatctgtgcatgacctcaatgataaacttgaaaatgaaattg
caaataaagattctatgcatcgacagactgaagataaaaaccgccagttacaggagcgcttggaattggcagagcaaaag
ctgcaacagacactgaggaaggcagagacgctcccggaggtggaggcggagctggcccagagggtggcagcgctttc
caaggctgaagagagacacggcaacattgaagaaaggttacgacagatggaagcacagttggaggagaagaatcaaga
actgcagcgggcaaggcaaagagaaaaaatgaacgaagaacataataaacgtttatcagacactgttgacaagctgctttc
agaatctaatgagaggcttcaacttcatcttaaagagagaatggctgctttggaagataagaactctcttttaagagaagttga
aagtgcaaaaaagcagttagaagaaacacaacacgataaggatcagcttgtcctaaacattgaagcactgagggctgaac
tagaccacatgagactaagaggtgcttcacttcatcatggccgaccccacttgggcagtgtcccagatttcaggttccccatg
gcagacggccacacagactcctacagcaccagtgcagtgctgcggcgcccacagaaaggccggctggcagccctgcg
agatgagccttccaaggtacaaactcttaatgagcaggattgggaacgtgcccagcaagctagtgtcttggcaaatgtagc
acaagcattcgagagtgatgctgacgtgtctgatggtgaagatgacagggacactctcctcagctcagttgacctgctatcg
cccagcgggcaggccgacgcgcacacactagccatgatgcttcaggagcagctggacgccatcaacaaagagatcagg
ttgattcaggaagaaaaagaaaatacagagcagcgggcagaggagattgaaagtcgagttggcagtggaagtctagaca
atcttggtcgttttagatcaatgagctccattcccccctaccctgcttcctcgcttgctagctcctcccctccgggcagtgggcg
ctccaccccacgaaggatccctcacagcccagctcgggaagtggacagactgggcgtcatgacccttttgccaccttcca
gagaagaggtacgagatgacaagacaaccataaagtgtgaaacctccccgccttcctccccgagagcccttcggttagac
cggctgcacaaaggggcgctgcacaccgtcagccacgaggacatcagggacataaggaactccacaggctcccaggat
ggtcccgtgagcaaccccagcagtagcaacagtagccaggactcgctccacaaagccccaaagaagaaaggcattaag
tcctccattggccgcttgtttggcaagaaagaaaagggccgacctggacaaactggcaaagaagcattaggacaagctgg
tgtttccgagacggataactcatctcaggatgccttgggacttagcaaattggggggacaggctgaaaaaaatcgtaaactt
caaaaaaagcatgaattgctggaggaagcccggagacaaggtttaccttttgcccaatgggacgggccaacggttgtggt
ctggctagagctctgggttgggatgccagcctggtatgtggctgcctgccgagcaaacgtgaaaagcggggccatcatgt
cggccctgtccgacacagagatccagcgtgagattggcatcagcaaccccctgcacaggctgaagctgaggctggccat
ccaggagatcatgtcgctgaccagcccgtctgccccgcccacatctagaacgacactcgcctatggggacatgaaccacg
agtggatcggcaacgagtggctccccagcctgggcctcccccagtaccgcagctacttcatggagtgccttgtagacgcc
aggatgctggaccacttgaccaagaaagaccttcgagggcagctgaaaatggtcgacagttttcacagaaacagtttccag
tgtggaattatgtgcctgagaaggttaaattatgaccggaaagaactggaaagaaaaagagaagaaagtcagagtgaaata
aaagacgtgcttgtttggagcaatgatcgagtgattcgctggatcctgtcaattggccttaaagaatatgcaaacaatcttata
gagagtggtgttcacggagcacttctggccttagatgaaaccttcgacttcagtgcactggcactgctgttacagatcccgac
gcagaacacacaggctcgtgctgtcttggaaagagaatttaacaaccttttggtcatggggactgatagaaggtttgatgaa
gatgatgataaaagctttaggagagcaccttcatggagaaaaaagtttagaccaaaggacattcgtggcttagctgctgggt
cagcagagactctccctgcaaacttccgggtgacttcttctatgtcttccccctctatgcagccaaagaagatgcagatggacggcaatgtatcaggaacacagaggttggattctgctacagtcaggacttactcctgctaa。
本发明的第二方面提供了所述分子标记物PPFIA1作为检测靶标,在制备肝细胞癌辅助诊断产品、肝细胞癌预后评估产品以及靶向治疗产品中的应用;与癌旁非肿瘤组织相比,PPFIA1基因在肝细胞癌细胞或组织中高表达。
进一步的,所述肝细胞癌的靶向治疗产品包括特异性敲低PPFIA1表达的物质。
进一步的,所述特异性敲低PPFIA1表达的物质为干扰PPFIA1表达的shRNA,所述干扰PPFIA1表达的shRNA的序列如SEQ ID NO.2~3所示。
SEQ ID NO.2:
5’-GAGGAGATTGAAAGTCGAGTT-3’;
SEQ ID NO.3:
5’-GATGACAAGACAACCATAAAG-3’。
本发明的第三方面提供了检测所述分子标记物PPFIA1表达水平的试剂在制备肝细胞癌辅助诊断产品、肝细胞癌预后评估产品中的应用。
进一步的,所述检测PPFIA1表达水平的试剂包括检测PPFIA1基因表达水平的特异性引物或PPFIA1蛋白的抗体。
进一步的,所述特异性引物:上游序列如SEQ ID NO.4所示,下游序列如SEQ IDNO.5所示。具体的:
SEQ ID NO.4:
5’-GCCCTGGCCCGAGCGGGCTC-3’;
SEQ ID NO.5:
5’-GTATCAGGTGCGGCGGAAGC-3’。
进一步的,所述PPFIA1的表达水平与肝细胞癌患者的预后良好呈负相关。
本发明的第四方面提供了一种用于肝细胞癌辅助诊断和/或预后评估的试剂盒,所述试剂盒中包含检测PPFIA1表达水平的试剂。
本发明相比现有技术的有益效果为:
1、本发明研究发现PPFIA1在肝细胞癌细胞和组织中表达量明显升高,因此以PPFIA1作为肝细胞癌的分子标记物,提出PPFIA1在制备肝细胞癌辅助诊断产品、肝细胞癌预后评估产品以及靶向治疗产品中的用途;相比现有肝细胞癌诊断方法,具有方便、快速、成本低、可重复、特异性高等优点,更有助于患者的诊断、治疗预后进行精细判断,为肝细胞癌患者的精准治疗提供了重要依据,具有广泛的临床应用价值。
2、本发明设计了特异性扩增PPFIA1的引物对,可特异性有效检测PPFIA1。
3、本发明设计了体外干扰PPFIA1的shRNA序列。
附图说明
下面结合附图和实施例对本发明作进一步说明:
图1为TCGA数据库中PPFIA1在肝细胞癌(n=336)和癌旁非肿瘤组织(n=50)中的配对(左)和非配对(右)mRNA表达差异示意图;
图2为采用Kaplan-Meier分析计算TCGA数据库中肝细胞癌患者(n=365)的PPFIA1生存曲线示意图;
图3为CCK-8法检测过表达PPFIA1基因的HepG2细胞增殖情况示意图及统计图;
图4为平板克隆法检测过表达PPFIA1基因的HepG2细胞集落形成情况示意图及统计图;
图5为转染短发卡RNA(shRNA)下调HepG2细胞中PPFIA1基因后,Western blot检测HepG2细胞中PPFIA1的表达示意图;
图6为图5所述HepG2细胞集落形成情况示意图及统计图;
图7为CCK-8法检测图5所述HepG2细胞增殖情况示意图及统计图;
图8为Transwell法测定过表达PPFIA1基因的HepG2细胞的迁移和侵袭能力示意图和统计图;
图9为过表达PPFIA1基因的HepG2细胞的形态学分析示意图;
图10为Transwell法测定图5所述HepG2细胞的迁移和侵袭能力示意图和统计图
图11为从过表达PPFIA1基因的HepG2细胞中提取总蛋白,并通过Western blot法检测EMT相关蛋白质生物标志物结果示意图;
图12为从图5所述HepG2细胞中提取总蛋白,并通过Western blot法检测EMT相关蛋白质生物标志物结果示意图。
图13为对照和过表达PPFIA1基因的HepG2细胞接种的裸鼠代表性生物发光图片和定量小鼠肝脏生物发光总通量统计示意图;
图14为图13所述的裸鼠肝脏的代表性图片(左)及肺转移结节数量统计示意图(右);
图15为苏木精和伊红(H&E)染色法对图13所述的裸鼠的肝脏和肺部染色的代表性图片;
图16为免疫组化染色法检测Ki-67和E-cadherin在图13所述的裸鼠的肝脏和肺组织中的表达示意图。
具体实施方式
为了更好地理解本发明,下面将结合附图对本发明做进一步地详细说明,以令本领域技术人员参照说明文字能够据以实施。
需要说明的是,下述具体实施例中所述实验方法,如无特殊说明,均为常规方法,所述试剂和材料,如无特殊说明,均可从商业途径获得。
下述具体实施例中主要试剂和材料包括:
浓盐酸、浓硫酸、氢氧化钠、二甲苯、碳酸氢钠、异丙醇、三氯甲烷、丙三醇、无水乙醇、甲醇、冰醋酸、葡萄糖、无水乙酸钠、氯化钙等购自北京化工厂;对苯二酚、2-巯乙基磺酸钠、多聚甲醛、二磷酸氯喹盐、过硫酸铵、焦碳酸二乙酯(DEPC)、结晶紫、考马斯亮蓝R250、氯化镁六水合物、氯化锰、氯化钠、硼酸、氢氧化钠、十二烷基硫酸钠(SDS)、四甲基乙二胺(TEMED)、脱氧胆酸钠、硝普钠、乙二胺四乙酸(EDTA)、原钒酸钠盐、HEPES、二甲基亚砜(DMSO)、戊巴比妥钠、二硫苏糖醇(DTT)、β-巯基乙醇、溴酚蓝、CHAPS、Tris、Tween-20、NP-40、Triton X-100、dNTP、氯霉素(Cam)等购自Sigma公司;氨苄青霉素(Amp)、卡那霉素(Kana)等购自北京鼎国昌盛生物技术公司,CCK-8试剂盒购自汉恒生物公司,Matrigel(基底胶)购自北京索莱宝生物公司,SPF级NU/NU裸鼠购自北京维通利华公司。
实施例1
选取TCGA(The Cancer GenomeAtlas)数据库336例肝细胞癌患者组织及50例癌旁非肿瘤组织数据,采用秩和检验分析PPFIA1基因的mRNA表达情况,得到如图1所示结果,说明PPFIA1在肝细胞癌患者组织中高表达。
使用Kaplan-Meier生存分析曲线分析计算TCGA数据库中365例肝细胞癌患者的PPFIA1基因表达量高低的生存曲线。如图2所示,结果显示PPFIA1基因表达量高可能提示肝癌患者的不良预后。
实施例2
本实施例首先构建获得敲低PPFIA1基因的HepG2细胞。
为了得到稳定敲低PPFIA1基因的HepG2细胞,具体步骤为:首先将干扰PPFIA1表达的shRNA进行慢病毒包被,收集病毒上清并进行过滤,对生长至对数生长期的HepG2细胞按照完全培养基:病毒上清体积为1:1的比例进行病毒感染,同时设置未感染的空白对照组,在37℃,5%CO2细胞培养箱中培养24小时后,加入嘌呤霉素抗生素进行筛选,待空白对照组细胞被抗生素全部杀死后,感染病毒组剩余的细胞即为稳定敲低PPFIA1基因的HepG2细胞,对该细胞进行扩增培养。
所述干扰PPFIA1表达的shRNA的序列如SEQ ID NO.2~3所示。
SEQ ID NO.2:
5’-GAGGAGATTGAAAGTCGAGTT-3’;
SEQ ID NO.3:
5’-GATGACAAGACAACCATAAAG-3’。
为探究PPFIA1基因在肝癌细胞增殖中的作用,通过细胞增殖CCK-8实验检测稳定高表达Flag-PPFIA1基因的HepG2细胞和稳定敲低PPFIA1基因的HepG2细胞的增殖能力,具体步骤为:将细胞消化和计数后,向96孔培养板中加入细胞,按照检测天数进行接种,并设置3个复孔。按照1:10的比例配制CCK-8工作液后将CCK-8工作液加至目的孔中,注意设置空白对照孔。在37℃,5%CO2细胞培养箱中孵育0.5-4h,吸出培养基上清,用酶标仪测定波长在420-480nm的吸光度,统计实验期间每天每组细胞的吸光度变化,进行统计分析。
通过CCK-8实验对稳定高表达Flag-PPFIA1基因或敲低的PPFIA1基因HepG2细胞的增殖情况进行观察,得到如图3及图7所示结果,说明高表达PPFIA1蛋白促进肝细胞癌细胞的增殖,而敲低PPFIA1蛋白表达则抑制肝细胞癌细胞的增殖。
进一步,为探究PPFIA1的表达量对于肝癌细胞克隆形成能力的影响,进行平板克隆实验。具体步骤为:将稳定高表达Flag-PPFIA1基因的HepG2细胞或敲低PPFIA1基因的HepG2细胞进行消化和计数后,将含10%FBS的细胞培养液加入至6孔培养板中,而后向每个孔加入800-1000个细胞,每组设置3个复孔,轻轻摇匀,培养5-10天。PBS清洗后加入4%多聚甲醛组织固定液,清洗再加入结晶紫染料染色,清水洗去浮色。待培养板彻底干燥后拍照,计数,并进行统计,分别得到如图4和图6所示结果,结果显示高表达PPFIA1促进肝细胞癌细胞克隆形成能力,而敲低PPFIA1蛋白表达则抑制肝细胞癌细胞克隆形成能力。
实施例3
分别从实施例2所述稳定高表达Flag-PPFIA1基因的HepG2细胞,和敲低的PPFIA1基因的HepG2细胞中提取总蛋白,进行蛋白质免疫印迹实验(Western Blot),具体步骤为:配制SDS-PAGE凝胶,在电泳槽中架好SDS-PAGE胶板后进行蛋白上样,电泳后将蛋白转移至PVDF膜,5%牛奶封闭,分别进行一抗(过夜),二抗(室温1h)孵育并用TBST缓冲液多次清洗后,置于曝光机进行化学发光。得到如图5所示结果,证明本申请实施例2提供的干扰PPFIA1表达的shRNA序列能够成功敲低该蛋白。
如图11和图12所示,通过一系列相关标记蛋白的结果显示高表达PPFIA1蛋白促进肝细胞癌细胞的上皮间质转化(EMT)和细胞增殖,而敲低PPFIA1蛋白表达则抑制肝细胞癌细胞的EMT和细胞增殖。
实施例4
对实施例2所述稳定高表达Flag-PPFIA1基因的HepG2细胞,和敲低PPFIA1基因的HepG2细胞,分别进行Transwell细胞迁移实验,具体步骤为:细胞消化和计数后,在小室配套的24孔培养板中加入20-25%FBS的细胞培养液,小室内加入带有0.5%FBS的细胞悬液,放置于细胞培养箱中进行培养,6-10h后收取Transwell小室,4%多聚甲醛固定,清洗后加入结晶紫染料,清水漂洗小室,观察、拍照与计数。
Transwell细胞侵袭实验,具体步骤为:提前用Matrigel处理小室,后续实验与Transwell细胞迁移实验相同,可适当延长小室收取时间。
得到如图8及图10所示结果,说明高表达PPFIA1蛋白促进肝细胞癌细胞的迁移和侵袭,而敲低PPFIA1蛋白表达则抑制肝细胞癌细胞的迁移和侵袭。
用显微镜明场观察上述细胞形态,并拍照记录。如图9所示,高表达PPFIA1的肝细胞癌细胞呈现更高程度梭形形态。
实施例5
为进一步探究高表达PPFIA1蛋白对肝脏肿瘤形成和发展的作用,本实施例进行裸鼠异种移植瘤实验,具体步骤为:将Firefly luciferase荧光素酶基因整合到预期观察的细胞染色体DNA上以表达荧光素酶,培养出能稳定表达荧光素酶的Flag-Vector或Flag-PPFIA1的HepG2细胞株。对裸鼠肝脏表面进行细胞接种。继续饲养小鼠,每隔7天对裸鼠进行活体生物发光成像及记录。接种后42天左右,脱颈处死裸鼠,解剖取肝脏和肺组织,拍照。根据肿瘤细胞的荧光强度进行统计分析并作图,比较不同处理组裸鼠成瘤能力大小。
如图13和图14所示,结果显示高表达PPFIA1蛋白促进裸鼠肝脏肿瘤形成及发展。
进一步对上述实验裸鼠的肝脏和肺组织进行HE染色实验和免疫组化染色。
HE染色实验具体步骤为:石蜡切片脱蜡水化,Harry’s苏木精染色后水洗。在酒精酸中漂洗2遍,随后用自来水后在伊红染料中染色。石蜡切片脱水(上行)后用中性树脂进行封片,然后在显微镜下观察并拍照。
如图15结果显示,高表达Flag-PPFIA1蛋白的裸鼠肝脏和肺组织中形成的肿瘤数目更多。
免疫组化染色具体步骤为:石蜡切片脱蜡水化(下行)后用3%的过氧化氢对内源过氧化物酶进行封闭,随后进行抗原修复及一抗和二抗的孵育。用DAB在镜下边观察边显色至合适程度,置于自来水中,再置于蒸馏水中。随后用Mayer’s苏木精对细胞核进行染色,再将切片放在水龙头下缓慢冲洗进行返蓝,直到细胞核呈现明显的蓝色。石蜡切片脱水(上行)后,用中性树胶进行封片,然后在显微镜下观察并拍照。
如图16结果显示,高表达PPFIA1蛋白促进肝细胞癌细胞的上皮间质转化(EMT)和细胞增殖。
实施例6
本实施例提供了一种用于肝细胞癌辅助诊断和/或预后评估的试剂盒,所述试剂盒中包含检测PPFIA1表达水平的特异性引物,PPFIA1是与肝细胞癌相关的分子标记物,PPFIA1基因的核苷酸序列如SEQ ID NO.1所示。
所述特异性引物:上游序列如SEQ ID NO.4所示,下游序列如SEQ ID NO.5所示。
SEQ ID NO.4:5’-GCCCTGGCCCGAGCGGGCTC-3’;
SEQ ID NO.5:5’-GTATCAGGTGCGGCGGAAGC-3’。
最后应说明的是,以上仅用以说明本发明的技术方案而非限制,尽管参照较佳布置方案对本发明进行了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的精神和范围。
Claims (9)
1.一种与肝细胞癌相关的分子标记物PPFIA1,其特征在于,PPFIA1基因的核苷酸序列如SEQ ID NO.1所示。
2.如权利要求1所述的分子标记物PPFIA1作为检测靶标,在制备肝细胞癌辅助诊断产品、肝细胞癌预后评估产品以及靶向治疗产品中的应用。
3.根据权利要求2所述的应用,其特征在于,所述肝细胞癌的靶向治疗产品包括特异性敲低PPFIA1表达的物质。
4.根据权利要求3所述的应用,其特征在于,所述特异性敲低PPFIA1表达的物质为干扰PPFIA1表达的shRNA,所述干扰PPFIA1表达的shRNA的序列如SEQ ID NO.2~3所示。
5.检测如权利要求1所述分子标记物PPFIA1表达水平的试剂在制备肝细胞癌辅助诊断产品、肝细胞癌预后评估产品中的应用。
6.根据权利要求5所述的应用,其特征在于,所述检测PPFIA1表达水平的试剂包括检测PPFIA1基因表达水平的特异性引物或PPFIA1蛋白的抗体。
7.根据权利要求6所述的应用,其特征在于,所述特异性引物为:上游序列如SEQ IDNO.4所示,下游序列如SEQ ID NO.5所示。
8.根据权利要求5所述的应用,其特征在于,所述PPFIA1的表达水平与肝细胞癌患者的预后良好呈负相关。
9.一种用于肝细胞癌辅助诊断和/或预后评估的试剂盒,其特征在于,所述试剂盒中包含检测PPFIA1表达水平的试剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311510675.6A CN117327708B (zh) | 2023-11-14 | Ppfia1在肝细胞癌治疗、诊断以及预后评估中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311510675.6A CN117327708B (zh) | 2023-11-14 | Ppfia1在肝细胞癌治疗、诊断以及预后评估中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117327708A true CN117327708A (zh) | 2024-01-02 |
CN117327708B CN117327708B (zh) | 2024-06-21 |
Family
ID=
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102827840A (zh) * | 2012-07-06 | 2012-12-19 | 暨南大学 | 抑制PPFIA1基因表达的siRNA及其应用 |
US20180274039A1 (en) * | 2017-03-02 | 2018-09-27 | Youhealth Biotech, Limited | Methylation markers for diagnosing hepatocellular carcinoma and lung cancer |
CN110904225A (zh) * | 2019-11-19 | 2020-03-24 | 中国医学科学院肿瘤医院 | 用于肝癌检测的组合标志物及其应用 |
CN112322736A (zh) * | 2020-11-17 | 2021-02-05 | 圣湘生物科技股份有限公司 | 一种用于检测肝癌的试剂组合,试剂盒及其用途 |
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102827840A (zh) * | 2012-07-06 | 2012-12-19 | 暨南大学 | 抑制PPFIA1基因表达的siRNA及其应用 |
US20180274039A1 (en) * | 2017-03-02 | 2018-09-27 | Youhealth Biotech, Limited | Methylation markers for diagnosing hepatocellular carcinoma and lung cancer |
CN110603329A (zh) * | 2017-03-02 | 2019-12-20 | 优美佳肿瘤技术有限公司 | 用于诊断肝细胞癌和肺癌的甲基化标志物 |
CN110904225A (zh) * | 2019-11-19 | 2020-03-24 | 中国医学科学院肿瘤医院 | 用于肝癌检测的组合标志物及其应用 |
CN112322736A (zh) * | 2020-11-17 | 2021-02-05 | 圣湘生物科技股份有限公司 | 一种用于检测肝癌的试剂组合,试剂盒及其用途 |
Non-Patent Citations (2)
Title |
---|
SERRA-PAGES, C.等: "NM_003626.1", 《GENBANK》, 19 March 1999 (1999-03-19) * |
YONGYIN GAO等: "High expression of PPFIA1 in human esophageal squamous cell carcinoma correlates with tumor metastasis and poor prognosis", 《BMC CANCER .》, vol. 23, no. 1, 9 May 2023 (2023-05-09), pages 417 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tian et al. | LncRNA PVT1 regulates growth, migration, and invasion of bladder cancer by miR‐31/CDK1 | |
Lai et al. | HIF-1α promotes autophagic proteolysis of Dicer and enhances tumor metastasis | |
Tao et al. | LncRNA HOTAIR promotes the invasion and metastasis of oral squamous cell carcinoma through metastasis‐associated gene 2 | |
Cabibi et al. | Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus | |
Protiva et al. | Pigment epithelium-derived factor (PEDF) inhibits Wnt/β-catenin signaling in the liver | |
Gao et al. | Mi RNA‐320a inhibits trophoblast cell invasion by targeting estrogen‐related receptor‐gamma | |
Lu et al. | Mir‐1287 suppresses the proliferation, invasion, and migration in hepatocellular carcinoma by targeting PIK3R3 | |
Jin et al. | Oncogenic role of MIR516A in human bladder cancer was mediated by its attenuating PHLPP2 expression and BECN1-dependent autophagy | |
Xu et al. | MiR-300 regulate the malignancy of breast cancer by targeting p53 | |
CN111518909B (zh) | Mettl2基因在制备检测结直肠癌氟尿嘧啶类药物治疗敏感性的试剂盒中的应用 | |
Zhao et al. | Role of Bcl-2 and its associated miRNAs in vasculogenic mimicry of hepatocellular carcinoma | |
Zhou et al. | Epstein–Barr virus (EBV) encoded microRNA BART8‐3p drives radioresistance‐associated metastasis in nasopharyngeal carcinoma | |
Yang et al. | Downregulation of circ_0000673 promotes cell proliferation and migration in endometriosis via the Mir-616-3p/PTEN Axis | |
Zhou et al. | miR‐942‐5p inhibits proliferation, metastasis, and epithelial‐mesenchymal transition in colorectal cancer by targeting CCBE1 | |
Huang et al. | miR-101 suppresses colon cancer cell migration through the regulation of EZH2 | |
CN103667441A (zh) | 一种Hsa-miR-145-5p试剂盒及其成熟体模拟物的应用 | |
CN110172462B (zh) | 一种对肿瘤的发生和发展具有促进作用的基因及其表达产物和应用 | |
Guan et al. | The IncRNA SCIRT promotes the proliferative, migratory, and invasive properties of cervical cancer cells by upregulating MMP‐2/‐9 | |
CN117327708B (zh) | Ppfia1在肝细胞癌治疗、诊断以及预后评估中的应用 | |
Shen et al. | Overexpression of JAB1 promotes malignant behavior and predicts poor prognosis in esophageal squamous cell carcinoma | |
CN117327708A (zh) | Ppfia1在肝细胞癌治疗、诊断以及预后评估中的应用 | |
CN102558336A (zh) | Prr11基因及其编码的蛋白和应用 | |
Lou et al. | Long non‐coding RNA KDM5B anti‐sense RNA 1 enhances tumor progression in non‐small cell lung cancer | |
CN112410429B (zh) | Fxyd3作为胃癌诊断标志物和治疗靶标的应用 | |
CN113498440A (zh) | 新型胰腺癌上皮间质转化标记物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |